ArticlePediatric cardiology2025
Reply to the Comments on "Biomarkers and Related Factors for the Diagnosis, Risk of Coronary Artery Lesions, and Resistance to Intravenous Immunoglobulin in Kawasaki Disease: An Umbrella Review of Meta-Analyses".
Article in Pediatric cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research on gamma globulin unresponsive Kawasaki disease: A review.World journal of clinical pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The article "Biomarkers and related factors for the diagnosis, risk of coronary artery lesions, and resistance to intravenous immunoglobulin in Kawasaki disease: an umbrella review of meta-analyses" offers valuable insights into diagnostic and therapeutic settings by overviewing various biomarkers associated with Kawasaki disease. There are some comments related to our umbrella review methodology, particularly PRIOR guidelines and GRADE framework. We clarify our choice of the PRISMA 2020 guidelines over PRIOR and explain the rigorous methodology used, which aligns with GRADE principles, ensuring robust and reliable findings. In addition, we address the suggestion for sensitivity analysis, noting that potential biases were managed through AMSTAR2 assessments, heterogeneity testing, and publication bias analysis.
Indexed as
Identifiers
39460754What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.